Q-omics provides the consensus-scored ZNF345 profile across patient tissues and cancer cell-line models. ZNF345 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF345 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF345 RNA expression shows 21,181 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where ZNF345 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF345 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF345 survival associations across molecular data types. ZNF345 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF345 RNA expression–survival associations across cancer types. High ZNF345 expression shows unfavorable associations in LGG, but favorable associations in UCS, HNSC, BRCA, LUAD and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF345 RNA expression.
This table summarizes ZNF345 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF345. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF345 shows lower tumor expression in THCA, UCEC, BRCA and HNSC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ZNF345 RNA expression in normal versus tumor tissue (log2 FC = −0.465, t-test p < 0.001).
This table shows molecular features associated with ZNF345 in patient tissues and cancer cell lines. In patient samples, ZNF345 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF345 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
